Median overall survival (OS) increased from 19.3 months with upfront immune checkpoint inhibition (ICI) to 41.3 months when a ...
Data presented as part of a poster at the SITC 2024 Conference SOUTH SAN FRANCISCO, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- ...
By Ayako Wakatsuki Pedersen, Ph.D., Senior Vice President of Translational Research at IO Biotech | Making the tumor microenvironment hostile to cancer cells and immune-suppressive cells may transform ...
AbCellera (Nasdaq: ABCL) today announced new data on its T-cell engager (TCE) platform, to be presented as a poster at the ...
FT836 Preclinical Data Shows Robust Antigen-mediated Expansion, Functional Persistence, and Durable Anti-tumor Activity in ...
Infinitopes' lead vaccine candidate ITOP1 is a novel, precision targeted, immunologically durable, 'off-the-shelf' cancer vaccine, designed to save lives by preventing disease recurrence in first-line ...
ALLO-316, a CD70-targeting CAR T-cell therapy, has demonstrated activity in patients with previously treated, advanced ccRCC.
Title: Comprehensive biomarker analyses from a Phase 1 study reveals marked tumor microenvironment modulation in patients with advanced solid tumors treated with MP0317, a FAP-localized CD40 agonistic ...
Q3 2024 Earnings Call Transcript November 7, 2024 4:30 AM ETCompany ParticipantsBruce Mackle - LifeSci Advisors, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback